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Prostanoids are important regulators of platelet aggregation and thrombotic arterial dis-
eases. Their involvement in the development of portal vein thrombosis, frequent in decom-
pensated liver cirrhosis, is still not investigated.
Methods
Therefore, we used pro-thrombotic venous milieu generation by bare metal stent transjugu-
lar intrahepatic portosystemic shunt insertion, to study the role of prostanoids in decompen-
sated liver cirrhosis. Here, 89 patients receiving transjugular intrahepatic portosystemic
shunt insertion were included in the study, and baseline levels of thromboxane B2, prosta-
glandin D2 and prostaglandin E2 were measured in the portal and the hepatic vein.
Results
While the hepatic vein contained higher levels of thromboxane B2 than the portal vein, levels
of prostaglandin E2 and D2 were higher in the portal vein (all P<0.0001). Baseline concentra-
tions of thromboxane B2 in the portal vein were independently associated with an increase
of portal hepatic venous pressure gradient during short term follow-up, as an indirect sign of
thrombogenic potential (multivariable P = 0.004). Moreover, severity of liver disease was
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inversely correlated with portal as well as hepatic vein levels of prostaglandin D2 and E2 (all
P<0.0001).
Conclusions
Elevated portal venous thromboxane B2 concentrations are possibly associated with the




Cirrhosis has been shown to be a pro- as well as an anticoagulatory condition[1]. Portal vein
thrombosis (PVT), in particular, has been described as a sign of progression in disease stage
[2]. However, factors related to PVT in cirrhosis have not been elucidated in detail.
Prostanoids are important regulators of the vascular tone, platelet aggregation and vascular
remodeling. For biosynthesis of certain prostanoids, arachidonic acid is converted by cycloox-
ygenases (COXs) to prostaglandin (PG) G2 and subsequently to PGH2[3]. In humans, there
are two COX isoforms: COX-1, expressed constitutively, and COX-2, which is inducible.
PGH2 is subsequently converted into the prostanoids and thromboxane (TX) depending on
specific synthases differentially expressed in each cell type. For example, TXA synthase
(TXAS) is mainly expressed in platelets which produce TXA2, a lipid mediator that promotes
proliferation of vascular smooth muscle cells and their constriction, platelet activation and
aggregation, and finally thrombosis[4]. Importantly, COX-2 and TXAS are induced by various
inflammatory stimuli, resulting in a close relationship between inflammation and regulation of
the vascular tone and platelet function[5]. Hence, increased production and activity of TXA2 is
known to contribute to the pathogenesis of diverse thrombotic arterial diseases, such as stroke
or coronary heart disease[6,7]. However, little is known about the role of TXA2 in the portal
vein and thrombosis in the portal compartment. One reason for this lack of information is that
access to this compartment is difficult. Insertion of transjugular intrahepatic portosystemic
stent shunt (TIPS) provides an opportunity to access the portal compartment. According to
current guidelines, the major indications for TIPS insertion are treatment and prevention of
variceal bleeding and/or intractable or refractory ascites[8,9]. Despite the development of poly-
tetrafluoroethylene (PTFE) covered stents, up to 15% of patients suffer from TIPS dysfunction
within the first two years[10]. Especially before the use of PTFE stents, bare metal stent inser-
tion was associated with early TIPS dysfunction, mainly due to pro-thrombotic milieu genera-
tion. We hypothesized that prostanoids may contribute to this pro-thrombotic milieu
generation. Therefore, blood samples were collected at first puncture of the portal vein during




We included eighty-nine patients with diagnosed liver cirrhosis and severe portal hyperten-
sion, undergoing TIPS insertion, in our study. Primary outcome was the increase in portal
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hepatic venous pressure gradient (PHPG) after TIPS insertion as a read-out of pro-thrombotic
milieu generation. All patients were treated between August 1996 and August 2003 in the Uni-
versity of Bonn, Department of Internal Medicine I, Germany. Patients, older than 18 years
with clinical signs of liver cirrhosis and a multidisciplinary defined indication for TIPS inser-
tion, were included in our trial. Exclusion criteria were the presence of systemic infection,
hepatic encephalopathy (higher than grade I), bilirubinemia (higher than 5mg/dl) or arterial
pulmonary hypertension. We used bare stents for TIPS insertion (8–10 mm Wallstent, Boston
Scientific, MA, USA), as previously described[11,12]. Control angiography was performed
after a mean of 14 days. Here, position and function of the stent was evaluated in patients with
significant decrease in portal venous flow or TIPS flow (N = 64). The process flow was previ-
ously specified as routine in the center’s protocol to optimize TIPS function[13]. During the
procedures, portal and hepatic venous pressures were invasively measured by the use of a pres-
sure transducer system (Combitrans, Braun, Melsungen, Germany) and a multichannel moni-
tor (Sirecust, Siemens, Germany). Per definition, the difference between the portal and hepatic
venous pressure was named portal hepatic pressure gradient (PHPG). Once, the right branch
of the portal vein was cannulated, we harvested blood from portal and hepatic vein in EDTA
tubes (N = 89) to obtain material for the analyses of TXB2, PGD2 and PGE2. All TIPS inser-
tions were performed without general anesthesia. After collection of the blood, we centrifuged
the samples at 3000 revolutions per minute for 15 minutes at 4˚C. Afterwards, plasma samples
were stored at minus 80˚C. Clinical patient data were recorded at their admission to the study.
For the analyses of common blood parameters (e.g. creatinine or bilirubin levels), we used
standard biochemical tests. The study protocol passed and has been approved by the local eth-
ics committee of the University of Bonn (029/13). All patients signed and agreed to all proce-
dures as declared in the study protocol. The final manuscript was reviewed by all authors.
Access to the study data was ensured and all authors approved the final manuscript.
Liquid chromatography mass spectrometry for prostanoid analysis
Two hundred μL plasma was porcupined with isotopically labeled internal standards (TXB2-
d4, PGD2-d4, PGE2-d4), 100 μL EDTA solution (0.15M) and 600 μL ethyl acetate, to quantify
levels of thromboxane B2, prostaglandin D2 and E2. Specimens were vortexed, and subse-
quently centrifuged at 20.000 g for 15 minutes. We removed the organic phase and rerun the
extraction by the addition of 600 μL ethyl acetate. After combination of the organic fractions, a
sparing stream of nitrogen was used for evaporation at a temperature of 45˚C. Reconstitution
of the residues was performed by the addition of 50 μL acetonitrile/water/formic acid
(20:80:0.0025, v/v/v) and transferred to glass vials. LC-MS/MS analysis was carried out using
an Agilent 1290 Infinity LC system (Agilent, Waldbronn, Germany) coupled to the hybrid tri-
ple quadrupole linear ion trap mass spectrometer QTRAP 6500+ (Sciex, Darmstadt, Germany)
equipped with Turbo V source operating in negative ESI mode. The chromatographic separa-
tion was carried out using a Synergi Hydro-RP column (150 × 2 mm, 4 μm particle size and 80
Å pore size; Phenomenex, Aschaffenburg, Germany). A gradient program was employed at a
flow rate of 300 μL/min. Mobile phase A was water/formic acid (100:0.0025, v/v) and mobile
phase B was acetonitrile/formic acid (100:0.0025, v/v). Seperation of the analytes was per-
formed under gradient conditions within sixteen minutes. The injection volume was 10 μL
and the gradient program started with 90% A for 1 min. The mobile phase A was decreased to
60% within 1 min. After 1 min biding, the mobile phase was further decreased to 50% within 1
min and another held for 2 min. Within 2 min, mobile phase A was further decreased to 10%
and held for 1 min. In the space of one minute, the initial conditions were restored. The col-
umn was re-equilibrated for 6 min. For mass spectrometric, parameters were set as follows:
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Source temperature 500 ˚C, ion spray voltage -4500 V, curtain gas 40 psi, nebulizer gas 40 psi
and turbo heater gas 60 psi. Both quadrupoles were running at unit resolution. Analyst Soft-
ware 1.6.3 and Multiquant Software 3.0.2 (both Sciex, Darmstadt, Germany) were used for
analysis and quantification. The following precursor-to-product ion transitions were used for
quantification: m/z 369.2!m/z 195.0 for TXB2, m/z 351.2!m/z 233.3 for PGD2 and m/z
351.2!m/z 315.0 for PGE2. Peak area of the corresponding internal standard was used for
correction of the peak area of each analyte. Calibration curves were constructed using linear
regression with 1/x2 weighting. The coefficient of correlation was at least 0.99. Variations in
accuracy were less than fifteen percent over the whole range of calibration, except for the low-
est limit of quantification, where a variation in accuracy of twenty percent was accepted.
Measurement of lipopolysaccharide levels
Using a commercial enzyme-linked immunosorbent assay kit (Cusabio), lipopolysaccharide
(LPS) serum levels were measured. Therefore, a specific antibody for LPS was precoated onto a
microplate, and 100 μL of sample or standards was plated for 2 hours at room temperature.
After incubation, samples were read at 450 nm. Values were expressed as picograms per millili-
ter; intra- and inter-assay coefficients of variation were 8% and 10%, respectively.
Statistical analyses
GraphPad Prism 5 for Windows (GraphPad Software, Inc.) or BIAS1 for Windows was used
for the performance of statistical analyses. Wilcoxon matched-pairs test was used for paired
intra-individual comparisons, namely portal versus hepatic vein prostanoid concentrations.
Group differences of unrelated groups were assessed by means of χ2 contingency tables or Wil-
coxon-Mann-Whitney U tests, as appropriate. Associations of outcomes with continuous vari-
ables were assessed in linear regression models. After univariate analyses, multivariate analyses
were performed for significant associations using a P value >0.1. Variables with P>0.1 were
discharged from the model. Survival analyses were performed using Cox proportional hazards
regression analysis. Correlations were assessed by the use of Spearmen/Kendall rang correla-
tion. P values< 0.05 were considered to be statistically significant.
Results
Baseline characteristics of patients
We included eighty-nine patients with a mean age of fifty-nine, undergoing BMS TIPS inser-
tion, in the study. Refractory ascites (N = 41 patients; 46%) was the major indication for TIPS
insertion, followed by secondary prophylaxis of variceal bleeding (N = 36 patients; 40%) and
treatment of hepatorenal syndrome (N = 6 patients; 7%). In six patients (7%) indication was
presence of both, esophageal variceal bleeding and ascites. Development of cirrhosis was
induced in most patients by alcohol abuse (51%), followed by viral hepatitis (7%) and primary
biliary cirrhosis (3%). Here, patients presented a mean MELD score of twelve points (range
6–33), and most patients were classified as Child-Pugh B at the time of study inclusion. The
mean survival time after TIPS insertion was 770 days. Please find the entire patients character-
istics in Table 1.
Prostanoid levels and relation to patient characteristics
Quantification of baseline TXB2 levels during TIPS insertion revealed significantly lower con-
centrations in the portal than in the hepatic vein (231.2 pg/mL vs. 726.9 pg/mL; P<0.0001). In
contrast, concentrations of PGD2 (295.7 pg/mL vs. 169.4 pg/mL; P<0.0001) and of PGE2
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(872.6 pg/mL vs. 693.4 pg/mL; P<0.0001) were significantly higher in the portal than in the
hepatic vein (Fig 1, Table 1). Since albumin binding of prostanoids has been shown to reduce
their bioavailability and activity in patients with liver cirrhosis[14], we assessed correlations of
TXB2, PGD2 and PGE2 with serum albumin concentrations. Here, albumin concentrations
correlated inversely with PGD2 and PGE2 concentrations in the portal vein (P = 0.04 each),
but neither with portal vein concentrations of TXB2, nor with hepatic vein concentrations of
TXB2, PGD2 or PGE2. Patient age did not affect portal or hepatic vein prostanoid levels. Corre-
lation of white blood cell count and portal vein TXB2 levels revealed a significant correlation
(P = 0.012). Furthermore, portal and hepatic vein levels of TXB2 correlated with platelet count
(PV: P = 0.014; HV: P = 0.002).
Table 1. Baseline characteristics of patients receiving TIPS.
Variables Patients (n = 89)
Age (years), mean (sd) 59 (9)
Male gender, n (%) 59 (66)
Etiology of cirrhosis alcohol, n (%) 45 (51)
viral hepatitis, n (%) 6 (7)
PBC, n (%) 3 (3)
cryptogenic, n (%) 35 (39)
BMI (kg/m2), mean (sd) 24.7 (5.1)
Systolic blood pressure (mmHg), mean (sd) 117 (21.3)
Diastolic blood pressure (mmHg), mean (sd) 68 (10.9)
Ascites, none/ mild/ severe/ unknown, n (%) 17/ 16/ 55/ 1 (19/ 18/ 62/ 1)
Esophageal varices, grade 0/ 1/ 2/ 3/ unknown, n (%) 9/ 19/ 38/ 19/ 4 (10/ 21/ 43/ 21/ 5)
Fundus varices, grade 0/ 1/ 2/ 3/ unknown, n (%) 23/ 22/ 26/ 18 (26/ 25/ 29/ 20)
TIPS indication (bleeding/ ascites/ HRS/bleeding and ascites), n
(%)
36/ 41/ 6/ 6 (40/ 46/ 7/ 7)
Hepatorenal syndrome (yes/ no/ unknown) 20/ 46/ 23 (22/ 52/ 26)
Albumin (g/dL), mean (sd) 3.1 (0.8)
Platelets (/nL), mean (sd) 124 (72.5)
Bilirubin (mg/dL), mean (sd) 1.7 (1.9)
Creatinine (mg/dL), mean (sd) 1.6 (1.2)
INR, mean (sd) 1.2 (0.2)
MELD score, mean (sd) 12 (7)
Child-Pugh class, A/ B/ C, n (%) 16/ 60/ 13 (18/ 67/ 15)
























PBC: primary biliary cirrhosis; MELD: model of end-stage liver disease; TIPS: transjugular intrahepatic
portosystemic stent shunt; INR: international normalized ratio; HRS: hepatorenal syndrome, BMI: body mass index,
sd: standard deviation; PV: portal vein; HV: hepatic vein.
https://doi.org/10.1371/journal.pone.0222840.t001
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The severity of liver disease (MELD score) was inversely correlated with the portal as well
as the hepatic vein levels of PGD2 and PGE2 (all P<0.0001). Here, creatinine showed a signifi-
cant inverse correlation with portal and hepatic vein levels of PGD2 and PGE2 and portal vein
levels of TXB2 (Table 2).
Association between prostanoid concentrations and portal hepatic venous
pressure gradient
The mean portal hepatic venous pressure gradient (PHPG) before TIPS insertion was 20.6
mmHg, and it decreased to a mean of 9 mmHg after TIPS insertion. At control angiography,
performed in 64 patients due to significant decrease in portal venous flow or TIPS flow, mean
PHPG measurement was 14.6 mmHg (Table 3). Out of 64 patients, 38 had shunt dysfunction
due to partial thromboses and received angioplasty. Next, uni- and multivariable regression
analysis was performed to identify predictors of PHPG increase after TIPS insertion (Table 4).
Of note, baseline TXB2 (P = 0.004) concentrations in the portal vein showed an independent
correlation with PHPG increase at short time follow-up. An additional predictor of PHPG
increase after TIPS insertion was baseline PHPG (P = 0.001). In contrast, no statistically signif-
icant association between portal vein concentrations of PGD2 and PGE2, or hepatic vein con-
centrations of TXB2, PGD2 and PGE2 was observed.
In a subset of 17 patients, we analyzed portal vein levels of lipopolysaccharide (mean 57.4
pg/ml +/- 9.6pg/ml). Spearmen’s rank correlation did not show significant correlations
between portal vein levels of lipopolysaccharide and portal vein levels of PGD2 (R = -0.26;
P = 0.31), PGE2 (R = -0.23; P = 0.37), or TXB2 (R = -0.02; P = 0.95).
Fig 1. Levels of Thromboxane B2 (A), Prostaglandin D2 (B) and Prostaglandin E2 (C) in portal compared to hepatic
vein. Wilcoxon matched-pairs signed-ranks test was used to compare differences. P-values<0.05 were considered
statistically significant. N = 89.
https://doi.org/10.1371/journal.pone.0222840.g001
Table 2. Correlation of prostanoids and different parameters.
Albumin WBC Platelets MELD score Creatinine
Rho P Rho P Rho P Rho P Rho P
Portal vein TXB2 -0.03 0.8 0.27 0.01 0.26 0.014 -0.08 0.5 -0.21 0.049
PGD2 -0.24 0.038 0.02 0.88 0.1 0.36 -0.48 <0.0001 -0.39 0.0002
PGE2 -0.23 0.039 0.004 0.97 0.06 0.59 -0.48 <0.0001 -0.37 0.0003
Hepatic vein TXB2 -0.06 0.62 0.007 0.53 0.33 0.002 -0.05 0.67 -0.16 0.14
PGD2 -0.2 0.08 -0.04 0.74 0.03 0.78 -0.47 <0.0001 -0.36 0.0006
PGE2 -0.16 0.15 -0.06 0.57 0.02 0.89 -0.49 <0.0001 -0.42 <0.0001
Spearman’s rank correlation test for correlation analysis. MELD: model for end-stage liver disease, WBC: white blood cell count; TXB2: thromboxane B2; PGD2:
prostaglandin D2; PGE2: prostaglandin E2. P-values <0.05 were considered statistically significant.
https://doi.org/10.1371/journal.pone.0222840.t002
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Predictors of survival after TIPS insertion
COX regression analysis of survival after TIPS insertion revealed baseline creatinine
(P<0.0001) concentrations as a negative predictor of survival (S1 Table). In detail, median sur-
vival of patients with baseline creatinine concentration�1.2 mg/dL was 236 days compared to
820 days in patients with creatinine concentration <1.2 mg/dL (P = 0.0005)(S1 Fig). However,
no significant association between prostanoid concentrations in the portal or hepatic vein and
patient survival after TIPS insertion was observed.
Discussion
The major finding of the present study is that concentrations of TXB2 are associated with an
increase of PHPG as an indirect sign of thrombogenic potential.
Portal hypertension (PHT) is associated with sequelae, such as ascites, variceal bleeding and
hepatorenal syndrome. Besides aggravation of portal hypertension due to cirrhosis, PHT can
also be impaired by the development of portal vein thrombosis, which frequently occurs in cir-
rhosis. These mechanisms are not fully understood. To the best of our knowledge there are no
Table 3. Change of portal hepatic venous pressure gradient through TIPS-insertion over time.
Character Before TIPS-insertion1
(n = 89)





PHPG, mean 20.6 <0.0001 9 <0.0001 14.6 <0.0001
1–10 mmHg, n 0 60 16
11–16 mmHg, n 14 25 28
17–20 mmHg, n 33 3 10
21–25 mmHg, n 32 1 9
>25 mmHg, n 10 0 1
Patient characteristics at time point 1 (baseline at insertion of TIPS), time point 2 (directly after TIPS insertion) and time point 3 (Follow-up angiography); TIPS:
transjugular intrahepatic portosystemic stent shunt; PHPG: portal hepatic venous pressure gradient. P-values <0.05 were considered statistically significant.
1 between time point 1 and 2
2 between time point 2 and 3
3 between time point 1 and 3.
https://doi.org/10.1371/journal.pone.0222840.t003
Table 4. Regression analysis of factors associated with increase of PHPG in control angiography compared to
baseline after TIPS-insertion.
univariable model multivariable model
β P-value β P-value
TXB2 (PV) 0.003 0.004 0.003 0.004
PGD2 (PV) 0.008 0.16
PGE2 (PV) -0.005 0.08 -0.014 0.15
TXB2 (HV) 0.0002 0.7
PGD2 (HV) 0.02 0.2
PGE2 (HV) -0.0003 0.9
Portal hepatic venous pressure gradient -0.54 0.002 -0.56 0.001
Multivariable linear regression analysis. TXB2: thromboxane B2; PGD2: prostaglandin D2; PGE2: prostaglandin E2;
PV: portal vein; HV: hepatic vein; P-values <0.05 were considered statistically significant. N = 64 patients
https://doi.org/10.1371/journal.pone.0222840.t004
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correlations of prevalence of thrombosis with portal pressure. Therefore, this study delivers
evidence for a potential mechanism leading to portal hypertension, cirrhosis and PVT.
TXA2 is a potent vasoconstrictor and a major activator of platelets synthesized by TXAS
from PGH2, a downstream metabolite of arachidonic acid which is preferentially catalyzed by
constitutively expressed COX-1. In turn, TXA2 is highly unstable and rapidly converted into
its inactive hydrolysis product TXB2, which is a good surrogate marker of TXAS activity and
TXA2 levels. The observation of higher TXB2 concentrations in the hepatic vein compared to
the portal vein might be explained by the abundance of COX-1 and COX-2 in liver sinusoidal
epithelial cells, which was observed in an animal model of liver cirrhosis[15]. Moreover, high
levels of phospholipase A2, an enzyme needed to catalyze the release of arachidonic acid from
membrane phospholipids, were observed in the cirrhotic liver of rats[16,17]. However, the
experimental evidence about inducible TXB2 release by Kupffer cells in fibrosis with a conse-
quent increase of portal pressure[18] supports our recent finding of elevated TXB2 levels in the
human hepatic vein in decompensated liver cirrhosis. At least in animal models, the distribu-
tion of these enzymes results in high levels of hepatic TXB2, which is in line with our finding of
a post-hepatic increase of TXB2 concentrations[19]. Indeed, aggregation of platelets in cirrho-
sis might lead to obliteration and parenchymal extinction, which is associated with portal
hypertension[20]. This observation was confirmed by the correlation between platelets and
TXB2. Also, in the portal vein, TXB2 seems to play a specific role, since it is independently asso-
ciated with an increase of PHPG and correlated with the white blood count. While in our
study, TXB2 concentrations in the portal vein were lower than in the hepatic vein, they must
be considered as high, since significantly lower TXB2 concentrations were observed in the sys-
temic circulation of healthy individuals (no data on portal venous TXB2 concentrations have
become available to date)[21,22]. Another possible explanation of the TXB2 correlation with
increase in PHPG is that TXB2 induced contraction of hepatic stellate cells[23].
Hence, the association observed here between TXB2 concentrations in the portal vein and
increase in PHPG after TIPS insertion appears to be biologically plausible. Furthermore, one
may speculate that high levels of TXB2 in the portal vein possibly predispose to the aggravation
of PHT and TIPS dysfunction, particularly since it is clearly linked to inflammation, as sug-
gested by the white blood count correlation.
In contrast to TXB2, concentrations of PGE2 and PGD2 were higher in the portal than in
the hepatic vein. While we can only speculate on the functional basis of this observation, it is
known that the enzymes generating PGD2[24] and PGE2[25] are widely distributed in various
tissues and, in particular, in inflammatory cells. Therefore, it appears plausible that the high
concentrations of PGD2 and PGE2 in the portal vein originate from bacterial translocation, a
hallmark of decompensated liver cirrhosis[26,27]. Although PGE2 has rather minor effects on
platelets, PGE2 effects on the vascular tone are the opposite of those of TXA2, as PGE2 signaling
results in vasodilation[28]. The inverse association, even if not statistically significant, between
PGE2 concentration in the portal vein and increase of PHPG after TIPS insertion further sup-
ports the potential pathophysiological relevance of our findings.
Interestingly, portal and hepatic vein levels of PGD2 and PGE2 were inversely correlated to
the severity of liver diseases as determined by the MELD score. While it is known that PGD2
and PGE2 are secreted by inflammatory cells, here, we did not find a correlation with the white
blood count. This can be explained either by immune paralysis due to advanced liver disease
with reduced PGD2- and PGE2 release by inflammatory cells[29] or the possibility that other
cells are the main producers of PGD2 and PGE2 in this pathological setting.
Evaluating inhibitors of prostanoid synthesis, namely of the TXA2-pathway, for prevention
of portal vein thrombosis will be of interest here. These anti-platelet agents not only have anti-
thrombotic functions in liver cirrhosis, but also anti-fibrotic and chemoprevention effects
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inhibiting hepatocellular carcinoma in animal models of liver disease and in clinical associa-
tion studies[30–33]. On the one hand, non-steroidal anti-inflammatory drugs (NSAID)
decrease concentrations of TXA2 by inhibition of COX and may reduce vascular tone in the
liver. On the other hand, administration of NSAIDs reduces renal blood flow as well as the glo-
merular filtration rate in cirrhotic patients with ascites and induces renal failure[34–36]. More-
over, the equilibrium between thrombosis and bleeding is very unstable in liver cirrhosis.
Therefore, one should be very careful with systemic drugs in cirrhosis, especially with COX
inhibition. Therefore, systemic administration of COX inhibitors is obsolete in cirrhosis and
ascites[9]. Since in animal models, COX inhibition seems to be useful in terms of portal hyper-
tension, this liver-specific approach may be considered, as previously shown for Rho-kinase
inhibition[37].
Our study has limitations. We were unable to include a control group of healthy individu-
als, because no medical interventions allowing for withdrawal of portal or hepatic venous
blood were performed in these individuals. Unfortunately, the comparison of peripheral pros-
tanoid levels of healthy controls, compensated and decompensated cirrhotic patients was not
focus of this study. Furthermore, we quantified total prostanoid concentrations in the knowl-
edge that albumin binding may also play a role in their bioavailability and activity, in particular
in patients with decompensated liver cirrhosis[14]. However, similar results were found when
PGD2 and PGE2 were normalized to the respective albumin levels in our study. Moreover, we
focused only on the stent thrombosis and other territories were not evaluated. Finally, we can’t
exclude the role of the bile leakage on the generation of the thrombogenic milieu and a possible
interaction with the prostanoids. Future studies may address all these limitations.
Conclusion
In conclusion, elevated portal venous TXB2 concentrations are possibly associated with the
extent of thrombogenic potential in patients with decompensated liver cirrhosis and offer suit-
able targets for future therapies.
Supporting information
S1 Table. Cox regression analysis of factors predicting mortality of patients receiving
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